ValiRx Acquires Global Rights to Novel Compound Targeted at Prostate Cancer

News   Jul 11, 2008

 
ValiRx Acquires Global Rights to Novel Compound Targeted at Prostate Cancer
 
 
 

RELATED ARTICLES

XenoGesis and BioAscent Forge Alliance to Offer Enhanced Integrated Drug Discovery Services

News

XenoGesis and BioAscent Discovery Limited have announced a collaboration to offer an enhanced range of integrated drug discovery services, including medicinal chemistry, biology and DMPK.

READ MORE

BioAscent Establishes Integrated Drug Discovery Services Offering

News

Dr Phil Jones to join as new CSO to lead company’s extended capabilities in medicinal chemistry and in vitro biosciences.

READ MORE

Lab Innovations returns to the NEC, Bimingham , UK

News

Save the date for the UK’s only lab-dedicated exhibition showcase!

READ MORE

 

Comments | 0 ADD COMMENT

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE